Compare BCPC & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BCPC | DYN |
|---|---|---|
| Founded | 1967 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 4.8B |
| IPO Year | 1995 | 2020 |
| Metric | BCPC | DYN |
|---|---|---|
| Price | $167.16 | $16.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 14 |
| Target Price | ★ $176.00 | $37.00 |
| AVG Volume (30 Days) | 136.8K | ★ 3.2M |
| Earning Date | 04-30-2026 | 05-04-2026 |
| Dividend Yield | ★ 0.55% | N/A |
| EPS Growth | ★ 20.87 | N/A |
| EPS | ★ 2.63 | N/A |
| Revenue | ★ $799,023,000.00 | N/A |
| Revenue This Year | $8.47 | N/A |
| Revenue Next Year | $4.89 | N/A |
| P/E Ratio | $63.82 | ★ N/A |
| Revenue Growth | ★ 13.56 | N/A |
| 52 Week Low | $139.17 | $11.92 |
| 52 Week High | $183.90 | $27.31 |
| Indicator | BCPC | DYN |
|---|---|---|
| Relative Strength Index (RSI) | 43.30 | 22.15 |
| Support Level | $167.19 | $14.34 |
| Resistance Level | $169.46 | $19.54 |
| Average True Range (ATR) | 3.02 | 1.09 |
| MACD | -0.03 | -0.25 |
| Stochastic Oscillator | 48.92 | 5.07 |
Balchem Corp is engaged in the development, manufacture, and marketing of specialty performance ingredients and products for various industries. The company's reportable segments are; Human Nutrition and Health, which generates maximum revenue, and provides human-grade choline nutrients and mineral amino acid chelated products through this segment for nutrition and health applications; Animal Nutrition and Health, which provides nutritional products derived from its microencapsulation and chelation technologies in addition to the essential nutrient choline chloride; and the Specialty Products segment includes re-packaging and distributing several performance gases and chemicals. Geographically, the company derives its key revenue from the United States and the rest from foreign countries.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.